西妥昔单抗治疗转移性结肠癌致重症肺炎一例并文献复习
|
摘要
<正>西妥昔单抗(cetuximab)是一种人/鼠嵌合型单克隆抗体,与表皮生长因子受体(epidermal growth factor receptor,EGFR)结合,抑制受体酪氨酸激酶(receptor tyrosine kinase, RTK)的磷酸化,从而阻断信号级联反应~([1])。过度表达的EGFR参与肿瘤细胞的增殖、凋亡和转移等过程,EGFR在70%～80%的结直肠癌中高表达~([2])。西妥昔单抗的使用提高了晚期结直肠癌患者的OS和PFS,然而其不良反应亦不能忽视。有关西妥昔单抗致肺部不良反应的报道多为回
引文
[1]HARRIS M.Monoclonal antibodies as therapeutic agents for cancer[J].Lancet Oncol,2004,5(5):292-302.DOI:10.1016/S1470-2045(04)01467-6.
[2]ZHANG W,GORDON M,LENZ H J.Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies[J].Ann Med,2006,38(8):545-551.DOI:10.1080/09546630601070812.
[3]CUNNINGHAM D,HUMBLET Y,SIENA S,et al.Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer[J].N Engl J Med,2004,351(4):337-345.DOI:10.1056/NEJMoa033025.
[4]SOULIERES D,GREER W,MAGLIOCCO A M,et al.KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFRtherapies[J/OL].Curr Oncol,2010,17(Suppl 1):S31-S40[2018-07-15].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2901795/.
[5]BOKEMEYER C,VAN CUTSEM E,ROUGIER P,et al.Addition of cetuximab to chemotherapy as first-line treatment for KRASwild-type metastatic colorectal cancer:pooled analysis of the CRYSTAL and OPUS randomised clinical trials[J].Eur J Cancer,2012,48(10):1466-1475.DOI:10.1016/j.ejca.2012.02.057.
[6]杨阳,邹多武,朱伟,等.西妥昔单抗联合化疗治疗晚期结直肠癌疗效的meta分析[J].中国肿瘤生物治疗杂志,2012,19(3):303-308.DOI:10.3872/j.issn.1007-385X.2012.03.015.
[7]QI W X,FU S,ZHANG Q,et al.Incidence and risk of severe infections associated with anti-epidermal growth factor receptor monoclonal antibodies in cancer patients:a systematic review and metaanalysis[J/OL].BMC Med,2014,12:203[2018-07-15].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236487/.DOI:10.1186/s12916-014-0203-5.
[8]De VOS F Y,DRIESSEN C M,JASPERS H C,et al.Cetuximab-induced pneumonitis in head and neck cancer patient[J/OL].Oral Oncol,2012,48(6):e17-e18[2018-07-15].https://linkinghub.elsevier.com/retrieve/pii/S1368-8375(12)00045-0.DOI:10.1016/j.oraloncology.2012.01.023.
[9]KANG H J,PARK J S,KIM D W,et al.Adverse pulmonary reactions associated with the use of monoclonal antibodies in cancer patients[J].Respir Med,2012,106(3):443-450.DOI:10.1016/j.rmed.2011.11.009.
[10]FUNAKOSHI T,SUZUKI M,TAMURA K.Infectious complications in cancer patients treated with anti-EGFR monoclonal antibodies cetuximab and panitumumab:a systematic review and metaanalysis[J].Cancer Treat Rev,2014,40(10):1221-1229.DOI:10.1016/j.ctrv.2014.09.002.
[11]RELLO J.Demographics,guidelines,and clinical experience in severe community-acquired pneumonia[J].Crit Care,2008,12(Suppl6):S2.DOI:10.1186/cc7025.
[12]RESTREPO M I,ANZUETO A.Severe community-acquired pneumonia[J].Infect Dis Clin North Am,2009,23(3):503-520.DOI:10.1016/j.idc.2009.04.003.
[13]中华医学会呼吸病学分会.中国成人社区获得性肺炎诊断和治疗指南(2016年版)[J].中华结核和呼吸杂志,2016,39(4):253-279.DOI:10.3760/cma.j.issn.1001-0939.2016.04.005.
[14]TORRES A,EWIG S,LODE H,et al.Defining,treating and preventing hospital acquired pneumonia:European perspective[J].Intensive Care Med,2009,35(1):9-29.DOI:10.1007/s00134-008-1336-9.
[15]SANDIUMENGE A,DIAZ E,BODI M,et al.Therapy of ventilatorassociated pneumonia.A patient-based approach based on the ten rules of“The Tarragona Strategy”[J].Intensive Care Med,2003,29(6):876-883.DOI:10.1007/s00134-003-1715-1.
[16]SCHLUETER M,JAMES C,DOMINGUEZ A,et al.Practice patterns for antibiotic de-escalation in culture-negative healthcare-associated pneumonia[J].Infection,2010,38(5):357-362.DOI:10.1007/s15010-010-0042-z.
[17]SAKAMOTO Y,YAMAUCHI Y,YASUNAGA H,et al.Guidelinesconcordant empiric antimicrobial therapy and mortality in patients with severe community-acquired pneumonia requiring mechanical ventilation[J].Respir Investig,2017,55(1):39-44.DOI:10.1016/j.resinv.2016.08.006.
[18]NICOLINI A,FERRAIOLI G,FERRARI-BRAVO M,et al.Early non-invasive ventilation treatment for respiratory failure due to severe community-acquired pneumonia[J].Clin Respir J,2016,10(1):98-103.DOI:10.1111/crj.12184.
[19]MARIK P E,ZALOGA G P.Adrenal insufficiency in the critically ill:a new look at an old problem[J].Chest,2002,122(5):1784-1796.DOI:10.1378/chest.122.5.1784.
[20]WU W F,FANG Q,HE G J.Efficacy of corticosteroid treatment for severe community-acquired pneumonia:a meta-analysis[J].Am JEmerg Med,2018,36(2):179-184.DOI:10.1016/j.ajem.2017.07.050.
[21]RAMSEY T D,GORMAN S K.Corticosteroids in the treatment of severe community-acquired pneumonia[J].Curr Infect Dis Rep,2014,16(5):405.DOI:10.1007/s11908-014-0405-1.
[22]SUBRAMANIAN M,MANJUNATH R,KILARA N,et al.Rituximab-induced subacute interstitial pneumonitis:a case report and review of literature[J].J Cancer Res Ther,2010,6(3):344-346.DOI:10.4103/0973-1482.73356.
[23]AOYAGI H,ITO H,HIGUCHI K,et al.A case of fatal interstitial pneumonia during FOLFIRI plus cetuximab therapy for liver metastasis of colon cancer[J].Gan To Kagaku Ryoho,2018,45(1):51-53.
[2]ZHANG W,GORDON M,LENZ H J.Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies[J].Ann Med,2006,38(8):545-551.DOI:10.1080/09546630601070812.
[3]CUNNINGHAM D,HUMBLET Y,SIENA S,et al.Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer[J].N Engl J Med,2004,351(4):337-345.DOI:10.1056/NEJMoa033025.
[4]SOULIERES D,GREER W,MAGLIOCCO A M,et al.KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFRtherapies[J/OL].Curr Oncol,2010,17(Suppl 1):S31-S40[2018-07-15].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2901795/.
[5]BOKEMEYER C,VAN CUTSEM E,ROUGIER P,et al.Addition of cetuximab to chemotherapy as first-line treatment for KRASwild-type metastatic colorectal cancer:pooled analysis of the CRYSTAL and OPUS randomised clinical trials[J].Eur J Cancer,2012,48(10):1466-1475.DOI:10.1016/j.ejca.2012.02.057.
[6]杨阳,邹多武,朱伟,等.西妥昔单抗联合化疗治疗晚期结直肠癌疗效的meta分析[J].中国肿瘤生物治疗杂志,2012,19(3):303-308.DOI:10.3872/j.issn.1007-385X.2012.03.015.
[7]QI W X,FU S,ZHANG Q,et al.Incidence and risk of severe infections associated with anti-epidermal growth factor receptor monoclonal antibodies in cancer patients:a systematic review and metaanalysis[J/OL].BMC Med,2014,12:203[2018-07-15].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236487/.DOI:10.1186/s12916-014-0203-5.
[8]De VOS F Y,DRIESSEN C M,JASPERS H C,et al.Cetuximab-induced pneumonitis in head and neck cancer patient[J/OL].Oral Oncol,2012,48(6):e17-e18[2018-07-15].https://linkinghub.elsevier.com/retrieve/pii/S1368-8375(12)00045-0.DOI:10.1016/j.oraloncology.2012.01.023.
[9]KANG H J,PARK J S,KIM D W,et al.Adverse pulmonary reactions associated with the use of monoclonal antibodies in cancer patients[J].Respir Med,2012,106(3):443-450.DOI:10.1016/j.rmed.2011.11.009.
[10]FUNAKOSHI T,SUZUKI M,TAMURA K.Infectious complications in cancer patients treated with anti-EGFR monoclonal antibodies cetuximab and panitumumab:a systematic review and metaanalysis[J].Cancer Treat Rev,2014,40(10):1221-1229.DOI:10.1016/j.ctrv.2014.09.002.
[11]RELLO J.Demographics,guidelines,and clinical experience in severe community-acquired pneumonia[J].Crit Care,2008,12(Suppl6):S2.DOI:10.1186/cc7025.
[12]RESTREPO M I,ANZUETO A.Severe community-acquired pneumonia[J].Infect Dis Clin North Am,2009,23(3):503-520.DOI:10.1016/j.idc.2009.04.003.
[13]中华医学会呼吸病学分会.中国成人社区获得性肺炎诊断和治疗指南(2016年版)[J].中华结核和呼吸杂志,2016,39(4):253-279.DOI:10.3760/cma.j.issn.1001-0939.2016.04.005.
[14]TORRES A,EWIG S,LODE H,et al.Defining,treating and preventing hospital acquired pneumonia:European perspective[J].Intensive Care Med,2009,35(1):9-29.DOI:10.1007/s00134-008-1336-9.
[15]SANDIUMENGE A,DIAZ E,BODI M,et al.Therapy of ventilatorassociated pneumonia.A patient-based approach based on the ten rules of“The Tarragona Strategy”[J].Intensive Care Med,2003,29(6):876-883.DOI:10.1007/s00134-003-1715-1.
[16]SCHLUETER M,JAMES C,DOMINGUEZ A,et al.Practice patterns for antibiotic de-escalation in culture-negative healthcare-associated pneumonia[J].Infection,2010,38(5):357-362.DOI:10.1007/s15010-010-0042-z.
[17]SAKAMOTO Y,YAMAUCHI Y,YASUNAGA H,et al.Guidelinesconcordant empiric antimicrobial therapy and mortality in patients with severe community-acquired pneumonia requiring mechanical ventilation[J].Respir Investig,2017,55(1):39-44.DOI:10.1016/j.resinv.2016.08.006.
[18]NICOLINI A,FERRAIOLI G,FERRARI-BRAVO M,et al.Early non-invasive ventilation treatment for respiratory failure due to severe community-acquired pneumonia[J].Clin Respir J,2016,10(1):98-103.DOI:10.1111/crj.12184.
[19]MARIK P E,ZALOGA G P.Adrenal insufficiency in the critically ill:a new look at an old problem[J].Chest,2002,122(5):1784-1796.DOI:10.1378/chest.122.5.1784.
[20]WU W F,FANG Q,HE G J.Efficacy of corticosteroid treatment for severe community-acquired pneumonia:a meta-analysis[J].Am JEmerg Med,2018,36(2):179-184.DOI:10.1016/j.ajem.2017.07.050.
[21]RAMSEY T D,GORMAN S K.Corticosteroids in the treatment of severe community-acquired pneumonia[J].Curr Infect Dis Rep,2014,16(5):405.DOI:10.1007/s11908-014-0405-1.
[22]SUBRAMANIAN M,MANJUNATH R,KILARA N,et al.Rituximab-induced subacute interstitial pneumonitis:a case report and review of literature[J].J Cancer Res Ther,2010,6(3):344-346.DOI:10.4103/0973-1482.73356.
[23]AOYAGI H,ITO H,HIGUCHI K,et al.A case of fatal interstitial pneumonia during FOLFIRI plus cetuximab therapy for liver metastasis of colon cancer[J].Gan To Kagaku Ryoho,2018,45(1):51-53.